Rotigotine patch with rivastigmine for mild to moderate Alzheimer's
Part of Brain & nervous system, Mental health clinical trials.
This trial tests if adding a rotigotine patch to your usual rivastigmine treatment can help with symptoms of Alzheimer's. It is for people with mild to moderate Alzheimer's who have been stable on rivastigmine for at least 3 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 85 years old.
- You have mild to moderate Alzheimer's disease, confirmed by a brain scan or spinal fluid test.
- You have been using the rivastigmine patch (at least 9.5 mg/day) for at least 3 months, or 1 month if you switched from donepezil.
- You have a caregiver who lives with you or is available to help with the medication.
- You do not have major depression, other types of dementia, serious heart or kidney problems, or certain other medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether RGn600 can help people with mild to moderate Alzheimer’s disease. You may be able to join if you meet age, test-score, scan, bloodwork, and safety requirements and can attend study visits with a regular caregiver.
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
This trial tests whether a special form of a dietary fat called tricaprilin can help people with mild-to-moderate Alzheimer's disease. It may provide an alternative or add-on to current treatments to help with memory and thinking.
This study compares two different ways of prescribing cholinesterase inhibitors (common Alzheimer's medications) to see which works better over time. If you or your loved one has mild to moderate Alzheimer's and has never taken these medications, this trial may help find the best treatment approach.
This trial tests a drug called masitinib to see if it can help people with mild Alzheimer's disease. You'd get either the drug or a placebo, and doctors will check if your daily living skills and memory slow their decline.
This Phase 2 study tests whether sargramostim (a GM-CSF related medicine) is safe and can slow or improve Alzheimer’s symptoms. You might be a good fit if you have mild or moderate Alzheimer’s, positive amyloid testing, and can complete frequent visits with a close caregiver who knows you well.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.